Urogen Pharma (NASDAQ:URGN) Hits New 1-Year High - Here's Why

Key Points

• Urogen Pharma's stock reached a new 52-week high of $21.71, with a last traded price of $21.42, reflecting increased investor activity with over 2.28 million shares traded.
• Analysts have given Urogen Pharma a consensus target price of $32.00, with most rating the stock as a "Buy," indicating potential for substantial growth.
• The company reported a loss of ($1.05) earnings per share in its last quarterly earnings, missing estimates, but exceeded revenue projections with $24.22 million generated.

Urogen Pharma (NASDAQ:URGN - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $21.71 and last traded at $21.42, with a volume of 2282153 shares. The stock had previously closed at $18.88.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on URGN shares. Oppenheimer set a $31.00 target price on Urogen Pharma and gave the stock a "buy" rating in a report on Friday, June 13th. Piper Sandler started coverage on shares of Urogen Pharma in a research report on Monday, August 18th. They issued an "overweight" rating and a $36.00 price target on the stock. D. Boral Capital restated a "buy" rating and issued a $25.00 price target on shares of Urogen Pharma in a research report on Tuesday, August 5th. Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. Finally, The Goldman Sachs Group set a $16.00 price target on shares of Urogen Pharma and gave the stock a "neutral" rating in a research report on Friday, June 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Urogen Pharma has an average rating of "Buy" and a consensus price target of $32.00.

Urogen Pharma Stock Performance

The business's 50 day moving average is $18.19 and its 200 day moving average is $12.90. The stock has a market cap of $869.23 million, a price-to-earnings ratio of -5.66 and a beta of 1.10.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.23). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%.The firm had revenue of $24.22 million during the quarter, compared to analyst estimates of $23.06 million. Research analysts expect that Urogen Pharma will post -3.12 earnings per share for the current year.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction on Monday, August 11th. The shares were sold at an average price of $17.69, for a total transaction of $176,900.00. Following the completion of the sale, the insider owned 148,229 shares of the company's stock, valued at $2,622,171.01. This trade represents a 6.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, General Counsel Jason Drew Smith sold 1,520 shares of Urogen Pharma stock in a transaction on Monday, September 8th. The shares were sold at an average price of $19.11, for a total transaction of $29,047.20. Following the sale, the general counsel directly owned 43,305 shares of the company's stock, valued at $827,558.55. This trade represents a 3.39% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 25,062 shares of company stock valued at $465,115 in the last three months. Company insiders own 4.70% of the company's stock.

Institutional Investors Weigh In On Urogen Pharma

Institutional investors and hedge funds have recently modified their holdings of the business. Osaic Holdings Inc. lifted its stake in shares of Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company's stock valued at $50,000 after purchasing an additional 3,070 shares during the last quarter. CWM LLC lifted its stake in shares of Urogen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after purchasing an additional 5,140 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Urogen Pharma in the 4th quarter valued at $67,000. GAMMA Investing LLC lifted its stake in shares of Urogen Pharma by 6,908.4% in the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after purchasing an additional 7,392 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Urogen Pharma by 422.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company's stock valued at $94,000 after purchasing an additional 5,571 shares during the last quarter. Institutional investors and hedge funds own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.